Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026

Immunic (IMUX) presented new clinical, biomarker, and preclinical data for vidofludimus calcium at MSToronto2026. Data showed durability of disability outcomes, neuroprotective effects, and reduced EBV-specific T-cell signatures. The company plans to initiate a Phase 3 program in progressive MS and expects top-line results from Phase 3 ENSURE trials by year-end 2026.

Immunic Inc. (IMUX) presented data on vidofludimus calcium at the MSToronto2026 conference. The Phase 2 CALLIPER trial's open-label extension showed a 6.5% discontinuation rate and consistent safety profile. Exploratory analyses indicated potential benefits in reducing Epstein-Barr virus-specific T-cell receptor matches and improving cognitive test scores. Preclinical data suggested neuronal survival benefits.

Immunic, Inc. (IMUX) presented new data on vidofludimus calcium at MSToronto2026. Phase 2 CALLIPER trial data showed durable disability outcomes and consistent safety. Preclinical data suggested neuroprotective effects. Exploratory analyses linked reduced EBV-specific T-cell signatures to improved cognitive performance. A novel disability measure suggested overall benefits in progressive MS patients. The company plans to initiate a Phase 3 program in progressive MS later this year.

Immunic Inc. (IMUX) will present data on vidofludimus calcium at the MSToronto2026 conference. The Phase 2 CALLIPER trial's open-label extension showed trends toward lower disability worsening risk for continuous treatment. Preclinical data suggests neuronal survival benefits. A post-hoc analysis linked reduced EBV-specific T-cell signatures to improved cognitive performance. The drug is in Phase 3 trials for relapsing multiple sclerosis, with results expected by late 2026.

Immunic (IMUX) will present new data on vidofludimus calcium (IMU-838) at MSToronto2026. Four abstracts cover long-term disability outcomes, EBV-related immune activity, cognition, and novel disability measurement. Phase 2 CALLIPER trial data show favorable disability outcomes with continuous treatment. Immunic aims to showcase vidofludimus calcium's potential in multiple sclerosis.

Immunic Inc. (IMUX) announced a private placement deal that could raise up to $400 million, with $200 million upfront. The funds will support clinical studies, operations, and future product launches. The stock surged 33% in premarket trading. The company plans to transition to a commercial-stage company and expects funds to last through 2027.